Tag: science
-
Deployment, SWaP-C and field-readiness — the outcome-layer bottleneck of quantum sensing: a record-sensitivity lab instrument and a deployable one are physically different things
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All SWaP, sensitivity and stability figures are attributed to their source and separated by tier: company datasheet, peer-reviewed metrology, or defense-agency program projection. Field tests and demonstrations are not operational products (analysis-standards §2).…
-
Atom-interferometry gravity and inertial sensing — drift-free ABSOLUTE gravimetry is the genuine, deployed quantum advantage; satellite, gradiometry and inertial navigation are the unproven extensions
Evidence-first notes on quantum sensing and deep tech, at the edge of the lab and the market. Information only — not investment advice. All sensitivity, deployment and error figures are attributed to the instrument, field trial or announcement that reported them; peer-reviewed data (Nature), company statements (Exail, Q-CTRL), agency projections (NASA/JPL, MoD) and preprints (arXiv)…
-
Magnetometry — NV vs OPM vs SQUID: the quantum sensor’s edge is not raw sensitivity but nanoscale spatial resolution, a different axis
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All sensitivity and material figures are attributed to the specific instrument, paper or announcement; peer-reviewed data (Physical Review Applied, Nano Letters, Nature Reviews Materials) are separated from company specifications (QuSpin QZFM) and trade…
-
Atomic clocks and timing — the one axis of quantum sensing that clearly beats the classical standard in the field, but the deployed instrument is not the record instrument
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All accuracy, stability and holdover figures are attributed to the instrument, paper or presentation reporting them; systematic uncertainty (accuracy), Allan deviation (stability) and holdover are separated throughout, and peer-reviewed lab records are kept…
-
The commercial paradox of anti-amyloid Alzheimer’s drugs — the surrogate is cleared and drugs are selling, but regulators, payers and societies brake it at the outcome layer (series close)
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All revenue, list-price, prescribing and regulatory figures are attributed to company earnings releases, CMS documents, EMA/PMDA/NMPA filings, or ICER/Value-in-Health reports. Lecanemab-versus-donanemab efficacy and safety comparisons are cross-trial (indirect) and are…
-
Plasma pTau217 and the actionability gap — diagnostic accuracy for Alzheimer’s has arrived and is regulated, but “does knowing change the outcome” is a separate, still-unproven axis
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All accuracy figures (AUC, concordance, NPV) are attributed to the specific study or assay, and diagnostic accuracy (how well a blood test identifies brain pathology) is kept separate throughout from…
-
CNS antisense oligonucleotides — tofersen missed its clinical primary yet was approved, and eplontersen missed its and was not: same modality, opposite regulatory outcome
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All trial results, reduction figures and safety events are attributed to the sponsoring trial, company or regulator; cross-trial and cross-indication comparisons are not head-to-head. Surrogate-biomarker results (neurofilament light) are kept…
-
Tau and next-generation targets — a closer target to cognition than amyloid, yet the intervention trials keep missing the primary endpoint
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All reduction and effect-size figures are attributed to the sponsoring trial or company; several are company press releases or conference presentations rather than peer-reviewed data (noted inline). The tau-versus-amyloid comparisons…
-
Anti-amyloid antibodies in Alzheimer’s — the amyloid is cleared, but the clinical curve bends only slightly
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All efficacy, biomarker and safety figures are attributed to the sponsoring trial or its primary publication. Amyloid clearance versus clinical benefit are kept strictly separate; cross-trial numbers are never ranked…
